Ibogaine treatment for addiction

1. Introduction

Version followed: the psychotherapy and safety frame described in published research and legal treatment settings. These are the St Kitts inpatient detoxification programme (Mash et al. 2018), the New Zealand prescription-access observational study (Noller, Frampton & Yazar-Klosinski 2018), the Brazilian clinic-plus-CBT model (Schenberg et al. 2014), and the Stanford MISTIC veteran study in Mexico (Cherian et al. 2024). The Texas-funded IMPACT trial programme (2025 on) is described from its enabling law and press coverage, because no protocol is documented in the sources. There is no treatment manual for ibogaine psychotherapy. Section 4 therefore gathers the procedures these programmes report and adds clinician-level practice marked [synthesis]. GITA 2015 guideline content, the Cherian et al. 2024 setting and adverse events, the Texas programme's 2026 status, Canada's legal status and psychiatric adverse events are drawn from the sources. GITA content comes from two secondary summaries (University of Arizona toolkit; UConn pharmacy lecture slides) because the guideline document itself was not found. Cherian's full Methods and the psychiatric case reports are not drawn on here; those points stay marked [uncertain].

Ibogaine is a psychoactive alkaloid from the West Central African shrub Tabernanthe iboga. Its long-lived active metabolite is noribogaine. Programmes use it mainly as an opioid detoxification and interruption treatment, followed by psychosocial aftercare [source: Mash et al. 2018; Koenig & Hilber 2015]. It is a medical procedure with a documented risk of sudden cardiac death, not a talking therapy. A psychotherapist's legitimate roles are: assessment, motivational work and preparation before the medical episode; supportive presence where a programme includes it; and integration, relapse prevention and aftercare afterwards. Medical screening, cardiac monitoring and all drug-related decisions belong to physicians [source: Alper et al. 2012; Koenig & Hilber 2015].

How change is thought to happen differs by source. Mash et al. describe the treatment as a transition between dependence and abstinence: it reduces withdrawal and craving and opens a window in which motivational counselling and aftercare referral can take hold [source: Mash et al. 2018]. Participants in the New Zealand study commonly reported gaining insight into their situation [source: Noller et al. 2018]. The Stanford team attributes the effects to increased brain plasticity, a hypothesis and not an established mechanism [source: Williams quoted in MDedge; uncertain]. Every programme opened treats the acute episode as a start that needs structured aftercare, not as a cure on its own [source: Mash 2018; Schenberg 2014; Noller 2018].

Legal and regulatory status (as of the sources' dates) [source: Colorado Sun 2025; Texas SB 2308 analysis; Lucid News 2026; Noller 2018; Schenberg 2014; Arizona toolkit; Health Canada 2017; Texas Tribune 2026]:

USA (federal): Schedule I. It can be used only under FDA-authorised research (an Investigational New Drug application). A federal executive order of April 2026 to speed review of psychedelic treatments, including ibogaine, is reported (AP, as cited by Wikipedia) [uncertain].
Texas: SB 2308 was signed in June 2025. It directs HHSC to fund a consortium (a drug developer, a university and a hospital) to run FDA trials for opioid use disorder, co-occurring substance use disorders and other conditions. State money must be matched by non-state funds. Trial sites must be universities or hospitals. In December 2025 HHSC awarded $50 million to a consortium co-led by UTHealth Houston and UTMB, called IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma). It has an opioid use disorder track led by UTHealth Houston, and a TBI/PTSD track for veterans and first responders at Dell Medical School and Baylor. Press reports mention intensive cardiac monitoring. On 31 March 2026 the Lieutenant Governor and House Speaker announced that no drug-company proposal had met the state's standards, so Texas would use the $50 million to run its own research programme with state medical researchers. The state did not say what the next steps were, and a Rice University fellow noted that the private-match requirement might block release of the funds without legal changes [source: Texas Tribune via News From The States 2026]. No trial protocol, IND, eligibility criteria or psychotherapy component is documented in the sources [uncertain].
Colorado: SB23-290 decriminalised personal possession and use, but sharing remains a crime. Use in regulated healing centres depends on a Natural Medicine Advisory Board recommendation, first discussed in June 2025.
New Zealand: Medsafe has classed ibogaine as a non-approved medicine since 2009, so it can be obtained on legal prescription.
Brazil: Schenberg et al. (2014) describe it as not controlled, and it was used within physician-supervised hospital care.
Mexico: Clinics operate, but sources describe the sector as unregulated.
Europe: Several countries ban it. Portugal is named as having legal clinics.
Canada: ibogaine is not authorised for use. Citing "serious and fatal adverse reaction reports" and a June 2015 public advisory not to use it, Health Canada added ibogaine and its salts, derivatives and analogues to the Prescription Drug List on 19 May 2017. Sale is allowed only on prescription, compounding is restricted, and inspectors can seize non-conforming products [source: Health Canada PDL notice 2017]. How this applies to clinics advertising to Canadians is not covered in official sources [uncertain].
Other jurisdictions are not covered in the sources [uncertain].

Cultural note: iboga has roots in Bwiti spiritual practice in Gabon. Religious and cultural authority over that practice rests with Bwiti practitioners and communities, not with clinicians or retreat operators. A Colorado state working group warned that Indigenous practitioners employed at profit-driven retreats may not be able to give fully informed consent [source: Colorado Sun 2025]. This guide does not describe ceremony.

2. Framework

No programme publishes a fixed number of psychotherapy sessions. The phases below are common to the sources; durations come from the named programme.

Phase A: Intake, motivation and referral (outpatient psychotherapy).

Goals: establish the diagnosis, the client's goals and their motivation. Assess psychiatric history and risk. Explain the medical risks honestly. Refer for medical screening.
Programme examples: Mash et al. recruited self-referred adults with DSM-IV opioid or cocaine dependence, with active use confirmed by urine screening. Schenberg et al. required strong motivation for abstinence, willingness to take part in psychotherapy, and family support. Noller et al. required voluntary, non-coerced treatment-seeking, age over 18, a named close affiliate who could corroborate information, and a commitment to 12 months of contact [source: Mash 2018; Schenberg 2014; Noller 2018].
Move on when the client gives informed agreement to medical screening and has a support person and an aftercare plan [synthesis].

Phase B: Medical screening (a physician's responsibility).

Exclusion criteria published by programmes include:
- history of stroke, epilepsy or psychotic disorders
- cardiovascular or liver disease
- HIV/AIDS (Mash)
- resting heart rate below 50 or long QT syndrome (Mash)
- pregnancy, recent surgery, uncontrolled hypertension or diabetes, cardiac arrhythmia, kidney or liver failure, Alzheimer's or Parkinson's disease (Schenberg)
- psychiatric comorbidity (Schenberg)
- schizophrenia or bipolar disorder, pre-existing cardiac illness, long baseline QTc, liver damage or cirrhosis, cerebellar dysfunction, epilepsy or seizure disorders, pregnancy, dementia or other organic brain disease, advanced respiratory disease, electrolyte abnormalities, untreated thyroid disorders (GITA 2015, as summarised in UConn lecture slides) [source: UConn slides on GITA 2015; guideline: uncertain]
Screening reported includes history, physical examination, laboratory tests including electrolytes, and an ECG [source: Mash 2018; Schenberg 2014; Alper 2012].
GITA 2015, as summarised, calls for a pre-treatment cardiac work-up with ECG, electrolytes within normal limits, screening for other cardiac risk factors, and laboratory screening. It also names classes of medicine the physician must review beforehand: those affecting heart rhythm or heart rate, those affecting the liver enzyme that clears ibogaine, psychiatric medicines and long-acting opioids. Changes to any medicine are the physician's decision alone [source: UConn slides on GITA 2015; Arizona toolkit; uncertain].
Cherian et al.'s veterans booked their own treatment at Ambio Life Sciences' clinic in Mexico. Stanford assessed them before and after but did not give the treatment. Screening criteria are not available in the sources [source: News-Medical on Cherian 2024; uncertain].
Koenig & Hilber list cardiac risk factors to screen for: female sex, long baseline QT, slow heart rate, electrolyte abnormalities (especially low potassium and magnesium), heart disease, inherited channel variants, and metabolic-enzyme (CYP2D6) variation [source: Koenig & Hilber 2015].
Alper et al. recommend that alcohol and benzodiazepine dependence be medically stabilised before treatment, because of withdrawal seizure risk [source: Alper 2012].
Move on only on medical clearance. A psychotherapist never makes this judgement.

Phase C: Preparation.

Goals: informed consent, expectations, a plan for the acute and early post-treatment period, and preparation of family and supports.
Schenberg's clinic required a period of documented abstinence with psychological follow-up before treatment. This was initially 30 days and later 60, completed at home or in residential care [source: Schenberg 2014].
Mash's programme combined informed consent with a psychosocial and addiction-severity assessment and structured psychiatric interviews. Interviews were repeated when intoxication or withdrawal made answers unreliable [source: Mash 2018].

Phase D: Acute treatment episode (medically supervised inpatient stay).

Settings described:
- a 12-day stay in a 12-bed freestanding facility with physicians, psychiatrists, a licensed therapist and consulting cardiology (Mash)
- a private hospital room with a physician present throughout (Schenberg)
- supervision over several days by the provider (Noller)
Programmes monitored with continuous ECG/telemetry and vital signs, and tracked adverse events for about a week afterwards (Mash) [source: Mash 2018; Schenberg 2014; Noller 2018].
GITA 2015, as summarised: continuous cardiac monitoring (telemetry) during treatment, a medical doctor present, staff trained in advanced cardiac life support, and emergency arrhythmia treatment on hand and/or a nearby emergency department [source: UConn slides on GITA 2015; Arizona toolkit; uncertain].
Cherian et al.: treatment at the Ambio clinic in Mexico under the clinic's medical monitoring. The study reported no serious or unexpected adverse events and no cardiac complications; headache and nausea were reported. Staff roles and monitoring details are not available in the sources [source: News-Medical on Cherian 2024; Unlimited Sciences abstract record; uncertain].
Koenig & Hilber stress extended ECG monitoring because QT prolongation can outlast the acute effects by more than a day, in some reports over a week [source: Koenig & Hilber 2015].

Phase E: Early recovery and integration.

Schenberg's patients were advised to avoid work, social activity and other people for at least a week afterwards. They then returned to the clinic for CBT. Extra sessions were added for intense craving, lapses, relapse or difficulty returning to family and old social circles [source: Schenberg 2014].
Mash's programme gave motivational counselling and referred people to aftercare and mutual-help groups such as 12-step [source: Mash 2018].
Noller's providers offered post-treatment supervision that monitored food intake, exercise and sleep [source: Noller 2018].

Phase F: Follow-up.

Noller et al. assessed at 1, 3, 6, 9 and 12 months using an addiction-severity interview, a depression inventory, urine screens and contact with the affiliate [source: Noller 2018].
Mash et al. followed up at about one month where possible [source: Mash 2018].
Most of Schenberg's male patients relapsed after their first treatment, so plan for continuing care from the start [source: Schenberg 2014].

3. Guiding principles

Medical safety comes first and is not yours to judge. Practical meaning: you never decide fitness for treatment. You make sure a qualified physician does, with an ECG and labs [source: Alper 2012; Koenig & Hilber 2015].
Honest informed consent includes the risk of death. Practical meaning: say plainly that sudden cardiac death has occurred, including in clinics [source: Koenig & Hilber 2015; Noller 2018].
Voluntariness. Practical meaning: screen out family pressure, court pressure or desperation-driven coercion. Noller's study required treatment-seeking without coercion [source: Noller 2018].
Ibogaine is a beginning, not a cure. Practical meaning: build the aftercare plan before treatment. Treat claims of single-session cure as a red flag [source: Mash 2018; MindSite 2024].
Involve a support person. Practical meaning: a named affiliate or family member supports safety, aftercare and accurate follow-up [source: Noller 2018; Schenberg 2014].
Non-directive presence during the acute phase. Practical meaning: in Schenberg's model the physician did not steer the experience but offered reassurance when needed. Follow the same stance if you are present [source: Schenberg 2014].
Full disclosure of substances and medicines. Practical meaning: concurrent drugs were found in most tested fatalities. Help the client tell the medical team everything, including long-acting opioid treatment and alcohol or benzodiazepine use [source: Alper 2012; Koenig & Hilber 2015].
Stay within the law and your scope. Practical meaning: where ibogaine is illegal, you offer assessment, education, harm reduction, referral and integration. You never arrange, facilitate or supply treatment [synthesis].
Respect cultural authority. Practical meaning: Bwiti practice belongs to its communities. Do not run, imitate or broker ceremony [source: Colorado Sun 2025; synthesis].
Measure, don't assume. Practical meaning: use standard addiction-severity, withdrawal and depression measures before and after, and check outcomes with collateral sources [source: Noller 2018].
Be sceptical of testimonials. Practical meaning: testimonials gathered right after treatment, when people are usually pleased, may not reflect outcomes once they return home [source: MindSite 2024].

4. Intervention inventory

The programmes opened name these components but publish no session scripts. The steps below put each named component into practice. Where steps go beyond what a source states, they are marked [synthesis]. Risk flags are repeated wherever the risky step appears.

4.1 Intake and motivational assessment

Purpose: establish the substance-use diagnosis, the client's goals, readiness and what they believe ibogaine will do. Mash's programme paired detoxification with motivational counselling. Schenberg's required strong motivation for abstinence and willingness to engage in psychotherapy [source: Mash 2018; Schenberg 2014].
Steps:
1. Take a full substance history: every substance, current pattern, any opioid agonist treatment, alcohol and benzodiazepine use, overdoses, withdrawal seizures.
2. Ask what the client has heard about ibogaine and where they heard it (influencers, a clinic website, peers).
3. Explore ambivalence and goals using standard motivational interviewing. Ask what abstinence would change and what they would lose.
4. Clarify whether ibogaine is the client's idea or someone else's.
5. Summarise and agree the next step: medical screening, or an evidence-based alternative first [synthesis for steps 2–5].
Example language (illustrative): "Before we get to whether ibogaine is right for you, tell me what you're hoping it will do that other treatment hasn't."
Watch for:
- magical expectations, such as "one night and I'm free"
- pressure from family or the courts
- desperation after a recent overdose
- Working signs: the client can describe goals beyond the acute episode and is willing to plan aftercare [synthesis].

4.2 Structured psychosocial and psychiatric assessment

Purpose: provide a baseline and identify psychiatric exclusions. Mash used an addiction-severity assessment and structured psychiatric interviews. Noller used an abbreviated Addiction Severity Index, a subjective opioid withdrawal scale and the Beck Depression Inventory-II. Psychotic disorders were excluded by Mash, and psychiatric comorbidity by Schenberg [source: Mash 2018; Noller 2018; Schenberg 2014].
Steps:
1. Give a validated addiction-severity measure and a depression measure, using licensed forms and without reproducing items.
2. Complete a structured diagnostic interview covering psychosis, bipolar disorder, suicidality and trauma.
3. Repeat any part done while the client was intoxicated or in withdrawal, as Mash's team did.
4. Send the findings, with consent, to the screening physician [source: Mash 2018; steps 1, 2 and 4 synthesis].
Example language (illustrative): "Some of these questions are routine for anyone considering this. They help the medical team decide whether it's safe for you."
Watch for:
- current suicidal ideation (of Cherian's 30 veterans, 19 reported lifetime suicidal ideation and 7 past attempts; 23 met PTSD criteria and 15 alcohol use disorder criteria)
- a history of psychosis, mania or bipolar disorder (excluded by Mash, and by GITA 2015 as summarised)
- inconsistent answers that suggest intoxication [source: News-Medical on Cherian 2024; Mash 2018; UConn slides on GITA 2015; synthesis].

4.3 Referral for medical screening (role boundary)

Purpose: make sure a physician assesses cardiac and medical risk. Published screening includes history, examination, labs including electrolytes, and an ECG. Exclusions include heart disease, long QT, slow resting heart rate, liver disease, epilepsy, stroke and others (listed in Section 2) [source: Mash 2018; Schenberg 2014; Alper 2012; Koenig & Hilber 2015].
Steps:
1. Write a referral letter to an addiction-medicine physician or the trial team. Include substance and medication history, psychiatric history and the client's goals.
2. Tell the client that cardiac screening and continuous cardiac monitoring are the minimum standard the literature describes.
3. Ask the client to bring the result back to you, so the plan stays coordinated [synthesis].
Example language (illustrative): "This is a decision for a doctor with your ECG and blood results in front of them, not for me or for a clinic's intake form."
Watch for:
- RISK FLAG: clients who want to skip screening
- clinics that accept people without an ECG and labs
- clients who hide medicines or long-acting opioid treatment from the medical team. Concurrent drugs were found in 8 of 11 tested fatalities [source: Alper 2012].

4.4 Informed-consent conversation

Purpose: the client's decision rests on accurate risk information. Koenig & Hilber recommend consent that clearly explains the risk of sudden cardiac death [source: Koenig & Hilber 2015].
Steps:
1. Cover legal status in the client's jurisdiction and in the destination.
2. Explain the documented harms in plain terms: arrhythmia and deaths, including in medical settings; nausea, vomiting and unsteady gait; prolonged cardiac risk after the acute effects end.
3. Explain that evidence comes mostly from small open-label studies.
4. Offer evidence-based alternatives such as opioid agonist treatment.
5. Check understanding with teach-back.
6. Record the conversation [source for content: Alper 2012; Koenig & Hilber 2015; Mash 2018; steps 1, 3, 4 and 5 synthesis].
Example language (illustrative): "People have died from heart-rhythm problems during or after ibogaine, sometimes a day or more later. I want you to hear that from me plainly."
Watch for: minimising ("that only happens at bad clinics"). Working signs: the client can restate the risks and the alternatives in their own words [synthesis].

4.5 Support-person (affiliate) and family involvement

Purpose: support safety, aftercare and accurate follow-up. Noller required a named close affiliate who could corroborate information. Schenberg required family support [source: Noller 2018; Schenberg 2014].
Steps:
1. With consent, meet the support person.
2. Explain their role: transport, presence during early recovery, noticing warning signs, attending aftercare planning.
3. Agree how they will contact you and medical services.
4. Address family hopes for a cure [synthesis for steps 1–4].
Example language (illustrative): "Your role isn't to supervise them. It's to be there in the first weeks, and to call for help if something seems medically wrong."
Watch for:
- a coercive family member
- a support person who also uses substances [synthesis]

4.6 Pre-treatment preparation and stabilisation

Purpose: enter treatment physically and psychologically stable, with a plan. Schenberg's clinic required a documented abstinence period with psychological follow-up before treatment, and later lengthened it. Alper et al. recommend medically stabilising alcohol and benzodiazepine dependence first [source: Schenberg 2014; Alper 2012].
Steps:
1. Hold weekly preparation sessions [synthesis on frequency].
2. Build coping skills for craving and distress (CBT methods, as in Schenberg's clinic).
3. Discuss what the acute experience may be like, in general terms. The sources describe long-lasting perceptual and dream-like effects, mental confusion, nausea and unsteadiness [source: Schenberg 2014; Mash 2018; MDedge on Cherian 2024].
4. Agree intentions for the episode.
5. Draft a written early-recovery plan: who, where, what to avoid, warning signs.
6. Leave any changes to medicines or opioid treatment entirely to the physician [synthesis].
Example language (illustrative): "Let's write down now what the first week after you come home looks like: where you'll sleep, who's with you, what you'll do if cravings hit."
Watch for:
- RISK FLAG: use of other substances before treatment, which is a risk factor in fatalities
- unmanaged alcohol or benzodiazepine dependence (seizure risk)
- a client in a poor physical state, as in the 2022 Cancún death [source: Alper 2012; MindSite 2024].

4.7 Provider safety review (when a client is considering a clinic)

Purpose: help the client judge a provider against the safety features the literature describes:
- physician-supervised medical setting (Schenberg)
- pretreatment ECG and labs (Alper, Mash)
- continuous cardiac monitoring for an extended period (Koenig & Hilber)
- a doctor present throughout, staff trained in advanced cardiac life support, emergency arrhythmia treatment and/or a nearby emergency department, and continuous cardiac telemetry (GITA 2015 guidelines, as summarised by the University of Arizona toolkit and UConn pharmacy lecture slides; the guideline document itself was not found) [source: Arizona toolkit; UConn slides on GITA 2015; uncertain on exact wording]
- medical staff and consulting cardiology (Mash)
Steps:
1. Give the client a question list. Who are the physicians and what are their licences? Is an ECG and blood work required, and who reviews it? Is the heart monitored continuously, and for how long after the effects end? Are staff trained in advanced cardiac life support? Is emergency resuscitation equipment on site, and how far is the nearest hospital? Which conditions and medicines lead them to refuse someone? What aftercare is provided?
2. Review the answers together.
3. Name red flags (Section 5 and the Harm account) [synthesis based on the sources above].
Example language (illustrative): "A safe provider should be glad you're asking these questions. If they're vague about heart monitoring, that's your answer."
Watch for:
- influencer marketing
- promises of a one-day cure
- acceptance of people in heavy active use without screening
- leaders with disciplinary histories [source: MindSite 2024].
This is harm-reduction education. Do not book, arrange or recommend a specific illegal or unregulated provider [synthesis].

4.8 Supportive presence during the acute episode (only within a legal, medically staffed programme)

Purpose: keep the client psychologically safe while medical staff monitor them. In Mash's programme a licensed therapist provided support during and after treatment. In Schenberg's, the client rested in bed in a quiet private hospital room. The physician checked in regularly, did not steer the experience, and offered reassurance as needed [source: Mash 2018; Schenberg 2014].
Steps:
1. Agree your role with the medical lead in advance. Medical staff own all monitoring and decisions.
2. Keep the room quiet and calm.
3. Use brief, non-directive reassurance and orientation ("you're safe, the team is here").
4. Do not interpret content during the acute phase.
5. Report any physical complaint straight to medical staff, including palpitations, fainting, chest discomfort, confusion or vomiting.
6. Help prevent falls: ataxia and tremor were seen in all of Cherian's participants and resolved within a day [source: MDedge on Cherian 2024; steps 1, 3, 4, 5 and 6 synthesis].
7. Touch policy: none is documented in the sources [uncertain]. Agree in writing beforehand that physical contact is limited to safety and medical needs, and keep a second staff member present [synthesis].
Example language (illustrative): "You don't need to do anything. Rest. If your body feels wrong in any way, tell us and the doctor will check."
Watch for:
- RISK FLAG: any cardiac or neurological sign is a medical matter. Do not calm it away psychologically.
- Psychological distress was usually manageable with reassurance in the reported series [source: Schenberg 2014; Mash 2018].

4.9 Early post-treatment rest and observation

Purpose: protect the client while cardiac risk persists and the client is fragile:
- QT prolongation can last more than 24 hours, in some reports over a week (Koenig & Hilber)
- adverse events were tracked for about a week (Mash)
- Schenberg's patients were advised to avoid work, social activity and other people for at least a week
- Noller's providers monitored food intake, exercise and sleep [source: Koenig & Hilber 2015; Mash 2018; Schenberg 2014; Noller 2018].
Steps:
1. Reinforce the medical team's discharge instructions.
2. Make sure the support person is present.
3. Hold a brief check-in by phone or video in the first days [synthesis].
4. Review sleep, eating, mood, craving and any physical symptoms.
5. Send the client back to medical care for any cardiac or neurological symptom [synthesis].
Example language (illustrative): "The heart effects can last longer than the experience itself, so this week is about rest, not catching up on life."
Watch for: fainting, palpitations, seizures, severe insomnia, emerging mania or psychosis, suicidal thoughts. On psychiatric adverse events: GITA 2015, as summarised, excludes people with schizophrenia or bipolar disorder, and a secondary encyclopaedia source describes low mood that can persist after the acute phase and sometimes mania [source: UConn slides on GITA 2015; Wikipedia "Ibogaine"]. A 2015 paper by Marta and colleagues (Am J Addict) is cited in the UConn slides but is not drawn on, so no case details are given here [uncertain]. Treat post-treatment mania, psychosis or severe depression as needing urgent psychiatric review [synthesis].

4.10 Experience elicitation interview

Purpose: capture the client's account and perceived benefits soon after treatment. Mash's team recorded and coded semi-structured elicitation interviews [source: Mash 2018].
Steps:
1. Within the first week or two, invite an open narrative: what happened, what stood out, what it meant.
2. Ask what the client now understands about their substance use. Insight was a common theme in Noller's sample.
3. Note perceived changes in craving and withdrawal.
4. Write down the client's own key phrases to use later in integration [source: Mash 2018; Noller 2018; steps 1, 3 and 4 synthesis].
Example language (illustrative): "Tell me about it in whatever order it comes. I'm interested in what it meant to you, not in judging it."
Watch for:
- over-reliance on visionary content as proof of cure
- shame about difficult content
- Working signs: the client links experiences to concrete life changes [synthesis].

4.11 Integration and relapse-prevention psychotherapy

Purpose: turn the post-treatment window into lasting change. Schenberg's patients returned for CBT after discharge. Extra sessions were offered for intense craving, lapses, relapse, or difficulty with family and old social circles. Mash's programme used motivational counselling [source: Schenberg 2014; Mash 2018].
Steps:
1. Hold weekly sessions [synthesis on frequency].
2. Map high-risk situations, people and places, and build coping plans using standard CBT relapse prevention.
3. Link insights from the experience to specific behaviour changes.
4. Rehearse refusal skills and changes to social networks.
5. Plan family reintegration.
6. Respond to lapses quickly with added sessions [source: Schenberg 2014 for themes; steps synthesis].
Example language (illustrative): "You said you saw clearly how using cut you off from your daughter. What's one thing this week that acts on that?"
Watch for:
- early relapse, which is common: most of Schenberg's men relapsed after the first treatment
- depression after a brief high [source: Schenberg 2014; synthesis].

4.12 Aftercare linkage and mutual-help referral

Purpose: connect the client to ongoing care. Mash referred clients to aftercare programmes and to community support groups such as 12-step [source: Mash 2018].
Steps:
1. Before treatment, book the first aftercare appointments.
2. Afterwards, confirm attendance.
3. Offer options: mutual-help groups, outpatient addiction services, an addiction-medicine physician for ongoing medical care.
4. Arrange psychiatric follow-up where indicated [synthesis].
Example language (illustrative): "Let's book your first two aftercare appointments now, before you go."
Watch for: the client dropping off contact once the acute benefit fades [synthesis].

4.13 Overdose-risk education after detoxification [synthesis]

Purpose: reduce the risk of fatal overdose if use resumes. This is standard harm-reduction practice after any opioid detoxification. It is not described in the ibogaine sources.
Steps:
1. Explain that lost tolerance makes a return to the previous amount dangerous.
2. Make sure the client and their support person have naloxone and know how to get emergency help.
3. Agree a plan for what to do after a lapse.
Example language (illustrative): "If you do use again, your body won't be used to it. That's when people overdose, so let's plan for that possibility."
Watch for: the client's belief that relapse is impossible.

4.14 Outcome monitoring and follow-up

Purpose: track progress and catch relapse. Noller assessed at 1, 3, 6, 9 and 12 months with addiction-severity and depression measures, urine screens and affiliate corroboration. Mash followed up at about one month [source: Noller 2018; Mash 2018].
Steps:
1. Repeat the baseline measures at agreed intervals.
2. With consent, check outcomes with the support person.
3. Review the measures with the client and adjust the plan [synthesis].
Watch for:
- discrepancies between self-report and collateral reports
- new medical complaints. Noller noted these may relate to stopping methadone [source: Noller 2018].

4.15 Harm-reduction consultation for clients who will use outside regulated settings [synthesis]

Purpose: reduce the risk of death and injury for clients who have decided to go to an unregulated clinic or use privately. This is a harm-reduction approach, using risks named in the sources.
Steps:
1. Assess without judgement.
2. Give the medical-risk information from 4.4.
3. Strongly advise a physician's assessment and an ECG before travel. Advise full disclosure of all substances and medicines to the treating doctor, and insistence on a setting with continuous cardiac monitoring and emergency capability [source for these features: Alper 2012; Koenig & Hilber 2015].
4. Warn that solitary or lay-supervised use and crude plant preparations of unknown composition are features of the documented fatalities [source: Alper 2012].
5. Make a safety plan: support person, emergency numbers, nearest hospital.
6. Offer integration sessions afterwards.
7. Document the advice.
8. Never give or help obtain substances, and never advise on amounts or how to take them [synthesis].
Example language (illustrative): "I can't help you get or use it, but I can help you understand the risks and be safer, and I'll be here afterwards."
Watch for: imminent travel without screening. Consider an urgent addiction-medicine referral.

4.16 Supporting a client after a frightening or harmful experience [synthesis]

Purpose: respond to distress, medical complications or a traumatic stay at an unsafe provider.
Steps:
1. Check medical status first and refer for medical review if there were cardiac or neurological symptoms.
2. Assess for acute stress, PTSD symptoms, depression and suicidality.
3. Offer a trauma-informed narrative and meaning-making work.
4. Address shame and disappointment about relapse.
5. Support any complaint the client wants to make to a regulator.
Example language (illustrative): "What happened to you there sounds frightening. Let's first make sure your heart is okay, then we can talk about the rest."

4.17 Clinician roles inside regulated trials (e.g. Texas IMPACT) [uncertain]

Status on 31 March 2026: Texas's leaders announced that no drug-developer proposal met the state's standards and that the state would run its own ibogaine research programme with state medical researchers. This builds on the December 2025 selection of UTHealth Houston with UTMB. The private-match requirement in the law may need to change before funds are released [source: Texas Tribune via News From The States 2026]. SB 2308 requires the consortium to train providers and use university or hospital trial sites [source: Texas SB 2308 analysis]. No trial protocol, IND, eligibility criteria, psychotherapy model, therapist roles or touch policies are documented in the sources [uncertain]. Clinicians should follow the trial's own protocol and IRB requirements, and should not assume the models above apply.

5. Handling problems

The sources say little about psychological problem-handling. Most guidance below is [synthesis], built on the risks the sources document.

Client insists on going ahead despite medical exclusion (heart disease, long QT, epilepsy):
- Name the exclusion as a safety finding, not a judgement.
- Explore what the client hopes ibogaine will solve, and offer evidence-based alternatives (opioid agonist treatment, residential care).
- If they still intend to go, switch to harm reduction (4.15) and document it.
- Several documented deaths involved pre-existing cardiovascular disease [source: Alper 2012; synthesis].
Client hides substances or medicines from the medical team:
- Concurrent drugs were found in most tested fatalities, and long-acting opioids and other substances may add to cardiac risk [source: Alper 2012; Koenig & Hilber 2015].
- Explain that disclosure protects their life, not their reputation.
- With consent, share the history directly with the physician [synthesis].
Non-adherence to preparation (keeps using, misses sessions):
- Review motivation, and whether the timeline is the client's own.
- In Schenberg's model, pre-treatment abstinence was a condition of entry. Supporting the medical team's decision to postpone is appropriate [source: Schenberg 2014; synthesis].
Overwhelm or panic during the acute episode:
- Calm, brief reassurance; a quiet room; no interpretation. Hand over immediately to medical staff for any physical symptom [source: Schenberg 2014; synthesis].
Disappointment or "it didn't work":
- Normalise it. Most men in Schenberg's series relapsed after one treatment.
- Return to relapse prevention. Do not frame another ibogaine treatment as the answer. That is a medical decision, not a therapeutic one [source: Schenberg 2014; synthesis].
Early relapse:
- Respond quickly with added sessions, as Schenberg's clinic did.
- Review the overdose-risk plan, because tolerance is reduced [source: Schenberg 2014; 4.13 synthesis].
Grandiosity, spiritual over-interpretation, or post-treatment mania or psychosis signs:
- Ground experiences in daily action. Attribute spiritual meanings to the client's own framework.
- Arrange urgent psychiatric assessment for manic or psychotic symptoms. GITA 2015, as summarised, excludes schizophrenia and bipolar disorder, and secondary sources report post-treatment low mood and sometimes mania [source: UConn slides on GITA 2015; Wikipedia "Ibogaine"; synthesis; primary case reports: uncertain].
Suicidality:
- In Cherian's sample of 30 veterans, 19 reported lifetime suicidal ideation and 7 past attempts [source: News-Medical on Cherian 2024].
- Use standard risk assessment before and after treatment, with safety planning and lethal-means counselling (storage and removal), and higher frequency of contact in the early weeks [synthesis].
Rupture (client feels judged for considering ibogaine, or for going against advice):
- Acknowledge the client's autonomy.
- Separate your safety concern from approval of the person, and repair openly [synthesis].
Family conflict on return:
- Schenberg's clinic added sessions for difficulty with family and old social circles. Offer family sessions and plan for old networks [source: Schenberg 2014].
Client returning from an unsafe provider with physical symptoms:
- Refer for urgent medical assessment. Delayed cardiac risk lasting days is documented [source: Koenig & Hilber 2015].
Commercial pressure or influencer-driven decision-making:
- Review the red flags (Harm account).
- Testimonials gathered right after treatment may not reflect later outcomes [source: MindSite 2024].
Clinician scope and legal risk:
- Where ibogaine is illegal, do not refer to, book or facilitate a specific provider. Provide harm reduction, assessment and integration.
- Check your licensing board's position [synthesis].

Harm account

What was actually done

1990–2008 fatalities (Alper, Stajić & Gill 2012):
- 19 deaths outside West Central Africa were temporally linked to ibogaine: Mexico 7, USA 4, France 3, Netherlands 2, UK, Germany and South Africa 1 each.
- Most took place in treatment facilities or private homes, often with lay providers. A few were in medical settings in Mexico and South Africa.
- 15 of the people who died were seeking opioid detoxification, several also with alcohol, cocaine or methamphetamine dependence. Two used ibogaine for spiritual or psychological purposes.
- Ages ranged from 24 to 54. Death came between 1.5 and 76 hours after ingestion.
- Some used crude plant preparations of unknown composition [source: Alper 2012].
After 2008 (Koenig & Hilber 2015):
- Further sudden deaths and at least eight cases of severe QT prolongation were reported, with QTc readings over 700 ms in some.
- Most of these progressed to ventricular tachycardia or fibrillation, many to torsades de pointes. Medical intervention appears to have saved them.
- In the newer reports, deaths came roughly 12–24 hours after intake [source: Koenig & Hilber 2015].
New Zealand (within the Noller et al. study):
- One participant died during treatment with a legal, fee-for-service provider.
- The Health and Disability Commissioner found a breach of duty of care.
- The coroner found the death "most probably related to a cardiac arrhythmia" [source: Noller 2018].
Cancún, 2022:
- A 49-year-old man with decades of opioid dependence died at the Beond clinic about a month after it opened. He had recently relapsed into heavy fentanyl use.
- The likely cause was reported as cardiac, linked to his fragile physical state.
- The clinic was promoted by influencers and celebrities, sometimes with claims that ibogaine ends addiction in a day.
- Its first chief medical officer later faced criminal charges, surrendered his medical licence and pleaded guilty to one charge [source: MindSite 2024, citing Rolling Stone; Colorado Sun 2025].
- MindSite/Rolling Stone describe him as a New Yorker, the Colorado Sun as from South Carolina [uncertain].

How it caused harm

Cardiac toxicity:
- Ibogaine and noribogaine block hERG potassium channels. This delays ventricular repolarisation and prolongs the QT interval, which can lead to torsades de pointes and fatal arrhythmia.
- Because noribogaine persists, risk can last days after the experience ends.
- Ibogaine also slows the heart rate [source: Koenig & Hilber 2015].
- Cardiac disease was a proximate or contributing cause in 6 of the 19 deaths reviewed by Alper et al. [source: Alper 2012].
Risk amplifiers:
- pre-existing heart disease, long baseline QT, slow heart rate
- low potassium (present in every tested QT case) and low magnesium (about half)
- female sex
- genetic variation in drug metabolism (CYP2D6)
- concurrent alcohol, cocaine, benzodiazepines or methadone and other QT-affecting substances [source: Koenig & Hilber 2015; Alper 2012]
Seizures:
- One death in Alper's series involved a generalised seizure, possibly from alcohol or benzodiazepine withdrawal [source: Alper 2012].
- Seizures are also reported with excessive exposure [source: Arizona toolkit].
Psychiatric adverse events:
- Secondary sources report low mood that can persist after the acute phase and, sometimes, mania [source: Wikipedia "Ibogaine"; uncertain].
- GITA 2015, as summarised, excludes people with schizophrenia or bipolar disorder. Read this as recognised risk of psychiatric destabilisation [source: UConn slides on GITA 2015; synthesis].
- Peer-reviewed case reports (e.g. Marta et al. 2015, cited in the UConn slides) are not drawn on, so no case details are given [uncertain].
Other findings in fatalities:
- liver disease, peptic ulcer, a brain tumour, obesity
- three Mexican deaths attributed to pulmonary embolism on inadequate autopsies [source: Alper 2012]
Unregulated provision:
- lay supervision; no ECG screening or continuous monitoring
- unknown product composition; concurrent drug use
- acceptance of medically fragile clients
- Deaths outside controlled settings have been linked to unsupervised administration practices, polydrug use, cardiovascular disease and variable product purity [source: Mash 2018; Alper 2012; MindSite 2024].
Underreporting:
- Alper et al. caution that deaths are likely underreported, especially with illegal use.
- An ibogaine physician quoted by MindSite claims mortality could reach 3% in untrained hands, and says he holds records of over 60 avoidable deaths. These figures are unverified and come from a person with a disciplinary history [uncertain] [source: Alper 2012; MindSite 2024].
Later counts:
- UConn lecture slides (2021) state that over 20 deaths were reported in the medical literature from 1990 to 2021, with polydrug use and heart disease common findings and some deaths in clinical settings [source: UConn slides].
- A 2022 review (Köck et al., J Subst Abuse Treat) is reported to have found 58 ibogaine-associated emergencies, including 38 deaths [source: Wikipedia "Ibogaine"; review: uncertain].
- Health Canada cited "serious and fatal adverse reaction reports" when it restricted ibogaine in 2017 [source: Health Canada 2017].
Who was most at risk:
- people with heart disease or electrolyte imbalance
- people using other drugs, including long-acting opioids, around treatment
- people with unmanaged alcohol or benzodiazepine dependence
- people in poor physical condition
- people treated by lay or unregulated providers [source: Alper 2012; Koenig & Hilber 2015; MindSite 2024].

Recognising it today

Red flags in a provider:
- no physician assessment, ECG or blood tests before treatment
- no continuous cardiac monitoring, or monitoring that stops when the visions end
- no doctor on site, no staff trained in advanced cardiac life support, no resuscitation equipment, no hospital access
- accepting people with schizophrenia, bipolar disorder or seizure disorders without medical and psychiatric review
- accepting people in heavy active use or with heart disease
- vague answers about exclusions
- influencer or celebrity marketing
- "one-day cure" claims
- testimonials collected at discharge
- leaders with disciplinary or criminal histories
- no aftercare [source: MindSite 2024; Alper 2012; Koenig & Hilber 2015; Arizona toolkit and UConn slides summarising GITA 2015].
Red flags in a colleague's practice:
- arranging or brokering trips to clinics where ibogaine is illegal or unregulated
- running or attending sessions outside a medically staffed setting
- presenting ibogaine as a cure
- advising clients on substances or amounts [synthesis].
Rebrandings to recognise:
- US and Canadian ketamine clinics that arrange travel to partner clinics in Brazil or Mexico [source: Arizona toolkit]
- retreats framed as Bwiti ceremony run for profit, which raises consent concerns for Indigenous practitioners [source: Colorado Sun 2025]
How legitimate versions differ:
- an FDA-authorised trial, a legally prescribed medical setting, or a hospital setting
- published exclusions, ECG and labs, physicians present, continuous cardiac monitoring for an extended period
- informed consent that names the risk of death
- structured psychosocial aftercare [source: Mash 2018; Schenberg 2014; Texas SB 2308; Koenig & Hilber 2015].

What to do instead and how to help those harmed

Safer alternatives:
- evidence-based treatment for opioid use disorder (opioid agonist treatment with psychosocial support), residential or outpatient addiction treatment, mutual-help groups [synthesis]
- for clients set on ibogaine, regulated research such as Texas's state-funded programme once trials are registered and recruiting, or legal medical settings. As of March 2026 the Texas programme was being restructured and no recruitment is announced in the sources [source: Lucid News 2026; Texas SB 2308; Texas Tribune 2026; uncertain on timing]
Assessment of affected clients:
- medical review for lasting cardiac or neurological symptoms
- screening for PTSD, depression, suicidality and relapse
- overdose-risk planning after lost tolerance
- bereavement support for families of people who died [synthesis]
Treatment: trauma-informed therapy for frightening experiences or neglect at a clinic, relapse prevention, and family work [synthesis].
Ethical, reporting and legal duties:
- Follow your jurisdiction's rules on confidentiality and mandatory reporting.
- Support clients who want to complain to medical regulators or patient-rights bodies; in New Zealand this is the Health and Disability Commissioner, which upheld a breach finding [source: Noller 2018].
- Report a colleague's facilitation of illegal treatment to the appropriate licensing body where required.
- Report serious adverse reactions to the national medicines regulator where a reporting route exists. Health Canada based its 2017 restriction on such reports [source: Health Canada 2017; synthesis].
- Document harm-reduction advice.
- Never take part in supplying or arranging illegal treatment [synthesis].

Sources

Sources: